Literature DB >> 14660015

Na+-dependent high affinity binding of [3H]LY515300, a 3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid receptor inverse agonist.

Michael A Statnick1, Todd M Suter, Susan L Gackenheimer, Paul J Emmerson, Steve J Quimby, Donald R Gehlert, William J Wheeler, Charles H Mitch.   

Abstract

Analogues of 3,4-dimethyl-4-(3-hydroxyphenyl)piperidines are high affinity inverse agonists for micro-, delta- and kappa-opioid receptors. To characterize inverse agonist binding, we synthesized a high specific activity radioligand from this series, [3H]LY515300 (3-[1-((3-cyclohexyl-[3,4-3H(2)])-3(R,S)-hydroxypropyl)-3(R),4(R)-dimethylpiperidin-4-yl]phenol). In membranes expressing cloned human opioid receptors, [3H]LY515300 binding was saturable and exhibited low nonspecific binding. [3H]LY515300 bound with high affinity to the micro- (K(d)=0.07 nM), delta- (K(d)=0.92 nM) and kappa-(K(d)=0.45 nM) opioid receptors. High affinity [3H]LY515300 binding to all opioid receptors was Na(+)-dependent, a characteristic of inverse agonists. Displacement by standard opioid compounds yielded K(i) values consistent with their known opioid receptor affinities. Autoradiographic localization of specific [3H]LY515300 binding in rat and guinea pig brain was high in areas known to express high levels of opioid (particularly micro-opioid receptor) binding sites including the caudate, nucleus accumbens, and nucleus tractus solitarius. Thus, [3H]LY515300 is the first radiolabeled opioid receptor inverse agonist useful for the study of opioid receptors in cell lines and native tissues.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14660015     DOI: 10.1016/j.ejphar.2003.09.043

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists.

Authors:  F Ivy Carroll; Sachin Chaudhari; James B Thomas; S Wayne Mascarella; Kenneth M Gigstad; Jeffrey Deschamps; Hernán A Navarro
Journal:  J Med Chem       Date:  2005-12-29       Impact factor: 7.446

2.  Discovery of N-{4-[(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyl-2-methylpropyl}-4-phenoxybenzamide analogues as selective kappa opioid receptor antagonists.

Authors:  Chad M Kormos; Chunyang Jin; Juan Pablo Cueva; Scott P Runyon; James B Thomas; Lawrence E Brieaddy; S Wayne Mascarella; Hernán A Navarro; Brian P Gilmour; F Ivy Carroll
Journal:  J Med Chem       Date:  2013-05-16       Impact factor: 7.446

3.  1-Substituted 4-(3-Hydroxyphenyl)piperazines Are Pure Opioid Receptor Antagonists.

Authors:  F Ivy Carroll; Juan Pablo Cueva; James B Thomas; S Wayne Mascarella; Scott P Runyon; Hernán A Navarro
Journal:  ACS Med Chem Lett       Date:  2010-10-14       Impact factor: 4.345

4.  4β-Methyl-5-(3-hydroxyphenyl)morphan opioid agonist and partial agonist derived from a 4β-methyl-5-(3-hydroxyphenyl)morphan pure antagonist.

Authors:  F Ivy Carroll; Moses G Gichinga; John D Williams; Eyal Vardy; Bryan L Roth; S Wayne Mascarella; James B Thomas; Hernán A Navarro
Journal:  J Med Chem       Date:  2013-11-05       Impact factor: 7.446

5.  The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.

Authors:  D T Beattie; M Cheruvu; N Mai; M O'Keefe; S Johnson-Rabidoux; C Peterson; E Kaufman; R Vickery
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-06       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.